Clinical Trial Update: Effects Of Sitaxsentan On Proteinuria, 24-Hour Blood Pressure, And Arterial Stiffness In Chronic Kidney Disease Subjects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial updates the effects of sitaxsentan on proteinuria, 24-hour blood pressure, and arterial stiffness in chronic kidney disease subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Sitaxsentan (sitaxsentan)

Snippet

Sponsor: Pfizer | Conditions: Chronic Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2023-07-06